Clinical Trials
8 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03199885 2026-05-29
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07610720 2026-05-28
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07612215 2026-05-28
Elacestrant in Advanced Triple Positive Breast Cancer
NYU Langone Health
Phase 1/2 Recruiting
NCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT06686394 2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07459673 2026-05-22
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting